Evgen eyes an IPO do-over; Merck snags lung cancer nod for Keytruda;

@FierceBiotech: Spark soars on success of gene therapy study, shot at groundbreaking approval. Report | Follow @FierceBiotech

@JohnCFierce: That Shkreli scandal? Infecting Valeant and Mike Pearson as the industry runs away as fast as possible. New York Times article | Follow @JohnCFierce

> U.K. drugmaker Evgen is again planning to go public on the London exchange, looking to raise £5 million to support its pipeline. Earlier this year, the company nixed a move to raise £20 million through the same means. News

> Valeant Pharmaceuticals' ($VRX) drug pricing model has come under more scrutiny. More

> Merck's ($MRK) immuno-oncology treatment Keytruda won FDA approval to treat lung cancer, helping the company compete with a rival therapy from Bristol-Myers Squibb ($BMY). Story

Medical Device News

@FierceMedDev: ICYMI Friday: Investigational spinal cord implant bringing bodily sensation back to the lives of the paralyzed. Report | Follow @FierceMedDev

@EmilyWFierce: ICYMI from FiercePharma: FTC weighs in on Mylan case, saying generics tweaking may be anticompetitive. Story | Follow @EmilyWFierce

> Boston Scientific wins $200M stent patent infringement case against doctor. Report

> Europe grants its first CE mark for leadless pacemaker to treat left ventricle. Article

Pharma News

@FiercePharma: ICYMI: Merck's Keytruda gets FDA approval for NSCLC ahead of BMS' Opdivo but label is limited. Article | Follow @FiercePharma

@EricPFierce: Swiss CMO Seigfried completes $302M deal for BASF API plants. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Ackman's fund takes a beating on Valeant pricing worries. Item | Follow @CarlyHFierce

> Last-minute deal on drug exclusivity wraps up TPP negotiations. Story

> Valeant's price-hike strategy goes far beyond two high-profile increases. Article

Animal Health News

> International health groups vow renewed effort to eradicate rabies. Report

> FDA seeks veterinarians' input on antibiotics resistance. Item

> USDA: Deadly pig virus likely carried into U.S. from China. More

> Stem cell treatment proves promising in dogs with Crohn's-like disease. Article

> WHO chief Margaret Chan vows to boost preparedness for disease outbreaks. Story

Biotech IT News

> Mount Sinai, Yale roll out updates to Apple ResearchKit programs. Report

> Allergan taps NuMedii's digital discovery platform for psoriasis R&D. News

> Illumina readies paid-for BaseSpace tiers for large organizations. More

> Cloud Pharmaceuticals, Therametrics hook up for CNS drug discovery drive. Story

> Berg to apply AI drug discovery model to U.K.'s genome data repository. Article

Pharma Marketing News

> BioMarin eyes SG&A efficiency on Kuvan; no worries on rare-disease pricing. Item

> Want to get a warning letter from OPDP? Omit drug risks from your promos. Story

> Teva snaps up Gecko and its 'smart inhaler' to pump up respiratory meds. More

> Veeva scoops up rival Zinc Ahead to create mega-content management platform. Report

> Obstacles aside, Boehringer sees class-topping prospects for Ofev, Spiolto. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.